Brahmi (Bacopa monnieri): Benefits, Dosage & Safety
TL;DR
Brahmi is the Ayurvedic whole-plant drug from Bacopa monnieri, a traditional medhya rasayana. Three small randomized trials found modest effects: 300 mg/day for 12 weeks improved delayed word recall in adults 65+ (n=54); weight-based dosing slowed forgetting over 12 weeks (n=76). A 9-trial meta-analysis linked it to faster attention. Modest, gradual effects. Pregnancy safety data are lacking.
What it is
The name "brahmi" is a trap, so I will start there. The herb this page is about is Bacopa monnieri (Linn.) Wettst., a low, fleshy, creeping plant of marshes and wetlands across India. The Ayurvedic Pharmacopoeia of India defines the official drug as the dried whole plant (synonym Herpestis monnieria; Sanskrit synonym Sarasvatī). (Tier 1: Ayurvedic Pharmacopoeia of India, Part I, Volume II, pp. 25–27, Government of India, Department of AYUSH.)
One taxonomic footnote, because labels lag behind botany. Modern classification puts Bacopa in the family Plantaginaceae. Older Ayurvedic literature, including the Pharmacopoeia itself, prints Scrophulariaceae, the family's former placement. Same plant. Updated filing. (Kew Plants of the World Online, the botanical authority; see Sources entry 7.)
Brahmi vs. gotu kola: the naming confusion, clarified
Here is the trap in practice. The U.S. National Institutes of Health's LiverTox database lists "Brahmi (a name also used for Gotu kola)" among Bacopa's common names. One vernacular label, two different species. The Ayurvedic Pharmacopoeia makes it worse by recording "Manduka Parni" (Hindi) and "Mandukaparni" (Kannada) as regional names for Bacopa monnieri, even though Centella asiatica (the plant most people mean by gotu kola / mandukaparni) is a separate species with its own monograph.
A published German case report of liver injury from Ayurvedic products illustrates the stakes: the tablets sold as "Brahmi" were described as containing either Eclipta alba or Bacopa monnieri, so the botanical identity of the product was unclear. That is an identity problem. Not proof of mislabeling or adulteration. I am careful with that distinction because it matters.
Practical rule: true brahmi is Bacopa monnieri; gotu kola is Centella asiatica. Check the Latin binomial on the label, not just the common name. (Tier 2: NIH LiverTox, NIDDK; Tier 1: Teschke et al. 2009, case report with causality assessment, Annals of Hepatology; Ayurvedic Pharmacopoeia of India Pt. I Vol. II.)
Traditional use
Classical Ayurveda describes brahmi's action (karma) with a cluster of terms: medhya (promoting intellect), rasāyana (rejuvenative), matiprada (bestowing understanding), āyuṣya (promoting longevity), among others. The Pharmacopoeia's therapeutic uses include mānasavikāra (disorders of the mind), plus kuṣṭha (skin disorders), jvara (fever), śopha (swelling), pāṇḍu (anemia-like conditions), and prameha (urinary/metabolic disorders). It turns up in classical formulations such as Sārasvatāriṣṭa, Brāhmī Ghṛta, Brāhmī Vaṭī, and Sārasvata Cūrṇa. (Tier 1: Ayurvedic Pharmacopoeia of India, Part I, Volume II.)
Western medical summaries record centuries of Ayurvedic use for anxiety, depression, memory loss, and epilepsy, describing it as a memory-and-learning enhancer, sedative, and anti-epileptic. Records of traditional practice. Not clinical proof. I will say that sentence every time it is needed, because the confusion between "used for centuries" and "proven effective" is the single most common error I see in herb writing. (Tier 2: NIH LiverTox; Tier 1: Calabrese et al. 2008, introduction reviewing traditional use.)
What modern research says
Memory and learning
Three randomized, double-blind, placebo-controlled trials. The strongest design available. Here is what each one actually found.
Roodenrys et al. 2002 (RCT, n=76, ages 40–65, 3 months): brahmi improved retention of newly learned information. The follow-up analysis is the interesting part. It suggested brahmi slowed the rate of forgetting rather than speeding up learning itself. Attention, verbal and visual short-term memory, retrieval of older knowledge, everyday memory, and anxiety did not move. Specific effect, not a general brain boost. (Tier 1: Neuropsychopharmacology 27(2):279–281.)
Calabrese et al. 2008 (RCT, n=54 enrolled / 48 completed, age 65+, 300 mg/day standardized extract for 12 weeks): the brahmi group scored better on delayed word recall (Rey Auditory Verbal Learning Test) than placebo, after controlling for baseline cognitive differences. (Tier 1: Journal of Alternative and Complementary Medicine 14(6):707–713.)
Stough et al. 2001 (RCT, double-blind, placebo-controlled, testing at 5 and 12 weeks): brahmi improved speed of visual information processing, learning rate, memory consolidation on the AVLT, and state anxiety, with maximal effects at 12 weeks. One caveat, and it is a real one: the publication reported the dose as 300 mg/day. Treat that dose figure cautiously. (Tier 1: Psychopharmacology.)
My read on the three together: a real, modest signal on retaining new information, in small trials, over months. Nothing here supports a quick fix.
Attention and speed of thinking
A 2014 meta-analysis pooled nine randomized, placebo-controlled trials (518 subjects total; 437 in the quantitative analysis) of chronic (12 weeks or longer) standardized Bacopa monnieri extract. Result: improved cognition, measured as shorter Trail-Making Test B time and faster choice reaction time. The published abstract formats the reaction-time estimate inconsistently, so no millisecond figures are reproduced here. I do not reproduce numbers I cannot verify.
The authors' own verdict: brahmi "has the potential to improve cognition, particularly speed of attention." Their explicit caution: only a large, well-designed head-to-head trial against an existing medication would settle it. I agree with both sentences. (Tier 1: Kongkeaw et al. 2014, meta-analysis, Journal of Ethnopharmacology 151(1):528–535.)
Anxiety, depression, and mood
Calabrese et al. 2008 (RCT, described above) found depression scores (CESD-10) and combined state-plus-trait anxiety scores fell over time in the brahmi group while rising in the placebo group. Heart rate followed the same pattern. Divided attention, immediate working memory, overall mood profile, and blood pressure did not change. Stough et al. 2001 (RCT) also reported reduced state anxiety (p<0.001). Small trials. Promising but preliminary mood findings. Not a basis for treating anxiety or depression. I am firm on that last sentence.
What the evidence does not show — and how long it takes
- A single dose showed no cognitive effect two hours after administration. The trials that worked used daily dosing for about 12 weeks. (Tier 1: Calabrese et al. 2008, reviewing Nathan et al., single-dose RCT.)
- Effects arrive slowly. Stough et al. found benefits at 12 weeks but not at 5 weeks. Expecting an immediate effect means expecting something the trials never demonstrated. (Tier 1: Stough et al. 2001.)
- Roodenrys et al. found no effect on attention, short-term memory, or everyday memory. The benefit was specific: retention of new information. (Tier 1: Roodenrys et al. 2002.)
Proposed mechanisms (cholinergic upregulation, antioxidant effects, modulation of stress hormones) come almost entirely from animal and in-vitro work. They are hypotheses, not established facts in humans. When a product page states them as facts, it is guessing. (Tier 1: Calabrese et al. 2008, reviewing preclinical literature.)
Dosage: what the sources actually used
This section reports doses found in Tier 1 sources. It is not a recommendation.
The Ayurvedic Pharmacopoeia of India lists 1–3 g of dried whole-plant powder. (Tier 1: API Pt. I Vol. II.) The clinical trials used different material. Calabrese et al. 2008 gave 300 mg/day of a 50:1 extract standardized to at least 50% bacosides A and B for 12 weeks (roughly a 15 g herb equivalent per tablet). Roodenrys et al. 2002 dosed 300 mg/day for participants under 90 kg and 450 mg/day for those over 90 kg, over a 12-week course. Stough et al. reported 300 mg/day; treat it cautiously. (Tier 1: Calabrese et al. 2008; Roodenrys et al. 2002.)
One practical warning, and I mean it: commercial products vary widely in standardization and actual bacoside content. "300 mg" on one label is not the same as "300 mg" on another. Talk to a qualified practitioner before use.
Safety & contraindications
- General tolerability: In small clinical trials, bacopa produced no serious or severe adverse effects. The NIH LiverTox review found it has not been linked to liver enzyme elevations during therapy and has not been implicated in clinically apparent liver disease (likelihood score E: unlikely cause). (Tier 2: NIH LiverTox, NIDDK.)
- Common side effects: Mostly gastrointestinal: nausea, stomach upset or pain, diarrhea. In Calabrese et al. 2008 (RCT), total adverse events were similar between brahmi (n=9) and placebo (n=10) groups, primarily stomach upset. In Keegan et al. 2023 (open-label, non-randomized), 4 of 35 participants (11%) stopped early for nausea/diarrhea. (Tier 1: Calabrese et al. 2008, RCT; Keegan et al. 2023, PMC10075090.)
- A caution from animal research: In male laboratory mice, oral brahmi at 250 mg/kg/day for 28–56 days reversibly suppressed spermatogenesis and fertility: sperm motility, viability, and counts fell, then recovered to control levels 56 days after stopping. Testosterone was unaffected. Human relevance is unknown. Animal finding, not an established human risk. I report it because it exists, not because you should panic about it. (Tier 1: Singh & Singh 2009, animal study, Contraception 79(1):71–79.)
- Pregnancy and breastfeeding: Safety is unknown. No adequate human data were found in Tier 1–3 sources. Discuss with a clinician before use.
- Drug interactions: No interaction data meeting Tier 1–3 standards was found. As general precautionary advice (not based on any located interaction evidence): combining brahmi with prescription medicines should only happen with a clinician's or pharmacist's input.
- Product identity risk: In the German case report, the botanical identity of tablets labeled "Brahmi" was unclear (described as either Eclipta alba or Bacopa monnieri). Buy from manufacturers that print the Latin binomial (Bacopa monnieri) and batch testing information. (Tier 1: Teschke et al. 2009.)
Frequently asked questions
Is brahmi the same as gotu kola?
No. True brahmi is Bacopa monnieri; gotu kola is Centella asiatica, a different species entirely. The mix-up is documented: the NIH lists "brahmi" as a name also used for gotu kola, and the Ayurvedic Pharmacopoeia records "Mandukaparni"-like regional names for Bacopa monnieri even though that name usually means Centella asiatica. Ignore the common name. Read the Latin on the label. I cannot say this often enough.
Does brahmi actually improve memory?
Three small randomized, placebo-controlled trials say: partly. Twelve weeks of brahmi extract improved delayed word recall and slowed the forgetting of newly learned information in adults (trial ages: 18–60, 40–65, and 65+). A 2014 meta-analysis of nine trials found faster attention and reaction time. Modest effects. Specific to certain memory tasks, not all of them. And no large definitive trial exists yet. Partly is the honest word, and I will keep using it.
How long does brahmi take to work?
About 12 weeks of daily use, based on the trials. Stough et al. saw cognitive benefits at 12 weeks but not at 5; a single-dose study showed nothing two hours after administration. Brahmi is not fast-acting. Immediate results are not something the trials demonstrated. If you want fast, this is the wrong herb.
What is the right brahmi dosage?
There is no established "right" dose. The Ayurvedic Pharmacopoeia lists 1–3 g of whole-plant powder. Clinical trials used 300 mg/day of standardized extract for 12 weeks (Calabrese); Roodenrys dosed 300 mg/day under 90 kg and 450 mg/day over 90 kg. Reported doses from sources, not recommendations. Products vary in strength. Consult a qualified practitioner.
What are the side effects of brahmi?
Gut trouble, mostly: nausea, stomach upset or pain, diarrhea. Small trials reported no serious or severe adverse effects, and the NIH found no link to liver injury. One animal study found reversible fertility suppression in male mice at high doses. Human relevance unknown. That is the full list as the evidence stands.
Is brahmi safe in pregnancy?
Unknown. No adequate human studies were found in authoritative sources. The animal fertility study in male mice does not answer the pregnancy question either. Discuss with a clinician before use while pregnant, nursing, or trying to conceive. Unknown means unknown, and I will not dress it up.
Voices
The classical voice
Charaka does not hedge about which department brahmi belongs to. The Rasayana compendium at carakasamhitaonline.com catalogues it directly: Bacopa monnieri (brahmi), "which promotes intellectual functions (medhya rasayana), is prescribed to treat mental disorders" (Charaka Samhita, Chikitsa Sthana 10/62). A published literary review of the Samhita references traces brahmi through Charaka's Prajasthapana group, his Aindriya Rasayana, and his Apasmara (epilepsy) and Kushtha chapters. It also notes that the Ashtanga Samgraha (Uttarasthana) counts brahmi among its best remedies for medhya (intellect) and smarani (memory). The classical record predates the first RCT by roughly two thousand years. What it records is use, not proof. Same rule as everywhere else on this page.
The modern voice
The trialists, in their own published words. Calabrese and colleagues, concluding the 12-week elderly trial: "This study provides further evidence that B. monnieri has potential for safely enhancing cognitive performance in the aging." Kongkeaw and colleagues, concluding the nine-trial meta-analysis: brahmi "has the potential to improve cognition, particularly speed of attention." They attached their own caution: only a large head-to-head trial against an existing medication would settle it. Two thousand years apart, the two voices are saying compatible things. Neither claims a miracle.
Sources
Tier 1 (Ayurvedic pharmacopoeia, peer-reviewed journals):
- Ayurvedic Pharmacopoeia of India, Part I, Volume II, pp. 25–27, monograph "Brāhmī (Whole Plant)" (Bacopa monnieri): botanical identity, synonyms, karma, therapeutic uses, dose 1–3 g powder, formulations. Government of India, Department of AYUSH. (Official publication; institutional holding at the Wellcome Collection: Pt. 1, Vol. II, digitized from the print edition, CC BY 4.0.)
Wellcome Collection Full monograph text (mirror of the official Ministry of Ayush e-book edition; the PDF carries the e-book's own note that monographs are reproduced from the official publication): miracledrinksclinic.com
- Kongkeaw C. et al. "Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract." Journal of Ethnopharmacology 151(1):528–535 (2014). PMID 24252493.
- Roodenrys S. et al. "Chronic effects of Brahmi (Bacopa monnieri) on human memory." Neuropsychopharmacology 27(2):279–281 (2002). PMID 12093601.
- Calabrese C. et al. "Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial." Journal of Alternative and Complementary Medicine 14(6):707–713 (2008). PMID 18611150. Full text.
- Stough C. et al. "The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects." Psychopharmacology (2001). PMID 11498727. Treat the exact Stough dose figure cautiously.
- Singh A., Singh S.K. "Evaluation of antifertility potential of Brahmi in male mouse." Contraception 79(1):71–79 (2009). PMID 19041444. (Animal study.)
- Kew Science, Plants of the World Online (family Plantaginaceae page), which names Bacopa monnieri (L.) Wettst. as a member of the family.
Kew · Plants of the World Online
- Teschke R., Bahre R. "Severe hepatotoxicity by Indian Ayurvedic herbal products: a structured causality assessment." Annals of Hepatology 8(3):258–266 (2009). PMID 19841509. (Case report; "Brahmi" tablets described as containing either Eclipta alba or Bacopa monnieri; product identity unclear.)
- Keegan et al. 2023, an open-label, non-randomized study in healthy elderly reporting commonly observed GI side effects (nausea, stomach pain, diarrhea) of bacopa supplementation; 4 of 35 participants (11%) stopped early for nausea/diarrhea. PMC10075090.
PMC · PMC10075090 Tier 2 (government health agencies):
- NIH LiverTox (National Institute of Diabetes and Digestive and Kidney Diseases): "Bacopa monnieri": traditional use summary, name confusion note ("Brahmi (a name also used for Gotu kola)"), adverse-effect and hepatotoxicity assessment (likelihood score E). Updated April 2024.
No Tier 3 sources were needed. No blogs, vendor sites, or content farms were used. The classical references below sit outside the tier system (use-records only).
Classical references (non-peer-reviewed; cited for use-records only, not evidence of efficacy):
- carakasamhitaonline.com, "Rasayana" (Charak Samhita online compendium): catalogues Bacopa monnieri (brahmi) as a medhya rasayana promoting intellectual functions, prescribed to treat mental disorders, citing Charaka Samhita, Chikitsa Sthana 10/62. (Community-edited wiki; use-record only.)
- Phadke A.S., "A Review on Brahmi (Bacopa Monnieri)," Indian Journal of Ancient Medicine and Yoga 16(4):177–183 (2023). DOI 10.21088/ijamy.0974.6986.16423.2. Traces Brahmi across Charaka Samhita (the Prajasthapana group, Aindriya Rasayana, Apasmara Chikitsa, and Kushtha Chikitsa) and notes Ashtanga Sangraha (Uttarasthana) listing Brahmi among the best remedies for Medhya and Smarani. (Literary review of the Samhitas; use-record only.)
Related herbs
Disclaimer
This article is for educational purposes only and is not medical advice. The traditional uses described are records of Ayurvedic practice, not proof of effectiveness. Herbal products can cause side effects and interact with medicines. Talk to a qualified healthcare practitioner before using brahmi, especially if you are pregnant, nursing, trying to conceive, taking prescription medicines, or managing a medical condition.